Proctology – an overview of new reports

Nowa Medycyna ◽  
2020 ◽  
Vol 27 (4) ◽  
Author(s):  
Przemysław Ciesielski ◽  
Mateusz Sala ◽  
Małgorzata Kołodziejczak

Every year, reports are published in medical journals to present new developments in the treatment of proctological diseases or related problems. The authors of this paper have reviewed the literature in the field of proctology spanning the last few years. A few publications have been selected and presented together with the authors’ practice-oriented comments. Research papers published in highly indexed scientific journals are subject to rigorous evaluation and review criteria, which makes them very credible. Nevertheless, there are often conflicting reports on similar or even the same surgical or pharmaceutical therapies. Time and clinical practice verify the value of these studies. The authors discuss reports on the application of chemical seton in the treatment of anal fistulas, FiXcision method in fistulectomy, outline contraindications to performing the LIFT procedure, and present the latest developments in stem cell therapy for fistulas and Botox treatment of anal fissures, as well as the application of new tools in proctological surgery. It is concluded that incorporating novel solutions into one’s own professional practice must be done with a certain amount of reserve, as their value is ultimately verified by time and distant outcomes of treatment.

2020 ◽  
Vol 49 (4) ◽  
pp. 825-838 ◽  
Author(s):  
Qi Hao Looi ◽  
Sue Ping Eng ◽  
Ling Ling Liau ◽  
Yin Sim Tor ◽  
Mohd Yazid Bajuri ◽  
...  

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Iman Razeghian-Jahromi ◽  
Anthony G. Matta ◽  
Ronan Canitrot ◽  
Mohammad Javad Zibaeenezhad ◽  
Mahboobeh Razmkhah ◽  
...  

AbstractWhile existing remedies failed to fully address the consequences of heart failure, stem cell therapy has been introduced as a promising approach. The present review is a comprehensive appraisal of the impacts of using mesenchymal stem cells (MSCs) in clinical trials mainly conducted on ischemic cardiomyopathy. The benefits of MSC therapy for dysfunctional myocardium are likely attributed to numerous secreted paracrine factors and immunomodulatory effects. The positive outcomes associated with MSC therapy are scar size reduction, reverse remodeling, and angiogenesis. Also, a decreasing in the level of chronic inflammatory markers of heart failure progression like TNF-α is observed. The intense inflammatory reaction in the injured myocardial micro-environment predicts a poor response of scar tissue to MSC therapy. Subsequently, the interval delay between myocardial injury and MSC therapy is not yet determined. The optimal requested dose of cells ranges between 100 to 150 million cells. Allogenic MSCs have different advantages compared to autogenic cells and intra-myocardial injection is the preferred delivery route. The safety and efficacy of MSCs-based therapy have been confirmed in numerous studies, however several undefined parameters like route of administration, optimal timing, source of stem cells, and necessary dose are limiting the routine use of MSCs therapeutic approach in clinical practice. Lastly, pre-conditioning of MSCs and using of exosomes mediated MSCs or genetically modified MSCs may improve the overall therapeutic effect. Future prospective studies establishing a constant procedure for MSCs transplantation are required in order to apply MSC therapy in our daily clinical practice and subsequently improving the overall prognosis of ischemic heart failure patients.


2020 ◽  
Vol 13 (4) ◽  
pp. 525-529
Author(s):  
Nicolas S. Piuzzi ◽  
Ahmed Emara ◽  
Jorge Chahla ◽  
Bert R. Mandelbaum

2021 ◽  
pp. 109-120
Author(s):  
Jonathan Slack

‘Expectations: realistic and unrealistic’ contemplates the goal of biomedical sciences to regenerate missing structures and to cure heart failure, diabetes, cancer, and neurodegeneration. The hype and controversy of human embryonic stem (ES) cells led the proponents of stem cell research to promise very rapid development of very radical cures. In reality progress will be slow. There are a number of lessons that we can learn from the development of haematopoietic stem cell transplantation (HSCT), which is one of the major applications of stem cell therapy in clinical practice.


2007 ◽  
Vol 28 (2) ◽  
pp. 361-379 ◽  
Author(s):  
Viranuj Sueblinvong ◽  
Benjamin T. Suratt ◽  
Daniel J. Weiss

2002 ◽  
Vol 59 (11) ◽  
pp. 571-576 ◽  
Author(s):  
Gratwohl

Die Transplantation hämatopoietischer Stammzellen umfasst heute Stammzellen aus Knochenmark, peripherem Blut oder Nabelschnurblut. Leukämien, Lymphoproliferative Erkrankungen, aplastische Anämie und schwere angeborene Erkrankungen des Knochenmarkes sind Hauptindikationen für allogene, lymphoproliferative Erkrankungen, Leukämien, solide Tumoren und schwere Autoimmunkrankheiten Hauptindikationen für autologe Transplantationen. Neue Verfahren wie reduzierte Konditionierung und selektive Gabe von Spenderlymphozyten eröffnen die Stammzelltransplantation auch für ältere Patienten und für solche mit vorbestehender Komorbidität. Wenn immer möglich, wird die Transplantation ab Diagnose in den Behandlungsplan integriert. Die Wahl des Verfahrens und des geeigneten Zeitpunktes wird nach individuellem Risikoprofil erstellt. Alter oder Diagnose sind nicht mehr alleinige Entscheidungskriterien. Als etablierte Therapieform dürfte die hämatopoietische Stammzelltransplantation als Modell dienen für Stammzelltransplantationen auch anderer Organe.


Sign in / Sign up

Export Citation Format

Share Document